DBV Technologies reported $212.05M in Equity Capital and Reserves for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Equity Capital And Reserves Change
DBV Technologies DBVT:US USD 212.05M 32.36M
Acadia Pharmaceuticals ACAD:US USD 425.69M 9.16M
Alnylam Pharmaceuticals ALNY:US USD -67638000 243.68M
Amarin AMRN:US USD 587.83M 7.78M
Biocryst Pharmaceuticals BCRX:US USD -242659000 29.43M
Biomarin Pharmaceutical BMRN:US USD 4.57B 63.71M
Esperion Therapeutics ESPR:US USD -294100000 2.4M
Galectin Therapeutics GALT:US USD -22335000 7.11M
Halozyme Therapeutics HALO:US USD 96.99M 196.18M
Insmed INSM:US USD -29959000 74.2M
Intercept Pharmaceuticals ICPT:US USD 107.68M 477.51M
IONIS PHARMACEUT IONS:US USD 594.36M 30.36M
Neurocrine Biosciences NBIX:US USD 1.54B 121.2M
Ptc Therapeutics PTCT:US USD -226904000 44.69M
Sarepta Therapeutics SRPT:US USD 430.84M 295.62M
Ultragenyx Pharmaceutical RARE:US USD 468.83M 209.24M
United Therapeutics UTHR:US USD 4.56B 243.8M
YTE INCY:US USD 4.23B 141.59M